Forget Ozempic & Wegovy. The Biggest Opportunity In Weight Loss Today. Lose Weight, Not Muscle $VERU

Forget Ozempic & Wegovy. The Biggest Opportunity In Weight Loss Today. Lose Weight, Not Muscle $VERU

30 Minuten

Beschreibung

vor 1 Jahr

Forget Ozempic & Wegovy. The Biggest Opportunity In Weight
Loss Today. Lose Weight, Not Muscle $VERU





Guest:


* CEO: Dr. Mitchell Steiner


* Title: Founder, Chairman, CEO, and President


* Website: www.verupharma.com


* Ticker: NASDAQ: Veru








* Bio:


Mitchell S. Steiner, M.D., F.A.C.S. has served as President and
Chief Executive Officer of Veru and as a director of the Company
since October 2016. Dr. Steiner was the co-founder of Aspen Park
and served as Aspen Park's Chief Executive Officer, President and
Vice Chairman of the Board from July 2014 to October 2016. From
2014 to 2016, Dr. Steiner was a consultant and then the
President, Urology and member of senior management of OPKO
Health, Inc. (NYSE:OPK) and had responsibilities for the launch,
marketing, sales and reimbursement of 4Kscore prostate cancer
test to urologists and primary care physicians. Dr. Steiner was
also the co-founder of GTx, Inc., a men's health and oncology
public company, where he served as Chief Executive Officer and
Vice Chairman of Board of Directors from 1997 to 2014. Dr.
Steiner is a Board Certified Urologist and a Fellow of the
American College of Surgeons and has held numerous academic
appointments, including Assistant Professor of Urology, Cell
Biology, and Pathology at Vanderbilt School of Medicine from 1993
to 1995 and Chairman and Professor of Urology, Director of
Urologic Oncology and Research and the Chair of Excellence in
Urologic Oncology at the University of Tennessee from 1995 to
2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry
from Vanderbilt University and an M.D. from the University of
Tennessee. He performed his surgical and urologic training at The
Johns Hopkins Hospital and postdoctoral research fellow in cell
biology at Vanderbilt School of Medicine.



Kommentare (0)

Lade Inhalte...

Abonnenten

15
15